Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Avant Research Associates LLC

Neither a doctor nor a teaching hospital

Research payments

$1,618,635

300 payments

Through program year 2025, Avant Research Associates LLC is reported as receiving $1,618,635 in research payments, across 300 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $15,200 1
2023 Research $42,967 9
2022 Research $107,966 17
2021 Research $167,422 57
2020 Research $542,264 123
2019 Research $742,817 93

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $732,739 145 payments
  2. AstraZeneca Pharmaceuticals LP $257,136 27 payments
  3. Novartis Pharmaceuticals Corporation $172,728 12 payments
  4. Vanda Pharmaceuticals Inc. $104,733 26 payments
  5. Pfizer Inc. $75,291 37 payments
  6. Genentech, Inc. $44,300 3 payments
  7. Zimmer Biomet Holdings, Inc. $41,126 7 payments
  8. Celgene Corporation $41,098 4 payments
  9. Chiesi USA, Inc. $29,041 10 payments
  10. Sanofi US Services Inc. $23,888 8 payments
Studies the money was for Research payments · program years 2019–2025
  1. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $395,490 44 payments
  2. A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $144,305 33 payments
  3. A 24 Week Multicenter Double Blind Placebo Controlled Dose Ranging Study to Investigate the Efficacy and Safety of Oral Qbw251 in COPD Patients on Triple Therapy (Laba/Lama/Ics) $105,047 3 payments
  4. Evaluating the Effects of Tradipitant Vs. Placebo in Atopic Dermatitis $104,733 26 payments
  5. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $65,088 8 payments
  6. A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) $64,257 4 payments
  7. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $55,940 2 payments
  8. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $54,808 10 payments
  9. A Phase 3B Randomized Doubleblind Doubledummy Active Controlled Multicenter Study Assessing the Efficacy and Safety of Abrocitinib Compared With Dupilumab in Adult Participants on Background Topical Therapy With Moderate to Severe Atopic Dermatitis $50,675 25 payments
  10. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $46,611 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record